Genetron Holdings Ltd. ADR (GTH): Price and Financial Metrics


Genetron Holdings Ltd. ADR (GTH): $1.57

-0.04 (-2.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GTH Stock Price Chart Interactive Chart >

Price chart for GTH

GTH Price/Volume Stats

Current price $1.57 52-week high $21.97
Prev. close $1.61 52-week low $1.25
Day low $1.56 Volume 63,100
Day high $1.65 Avg. volume 285,256
50-day MA $1.60 Dividend yield N/A
200-day MA $6.22 Market Cap 142.25M

Genetron Holdings Ltd. ADR (GTH) Company Bio


Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.


GTH Latest News Stream


Event/Time News Detail
Loading, please wait...

GTH Latest Social Stream


Loading social stream, please wait...

View Full GTH Social Stream

Latest GTH News From Around the Web

Below are the latest news stories about Genetron Holdings Ltd that investors may wish to consider to help them evaluate GTH as an investment opportunity.

Genetron Holdings (GTH) Investor Presentation - Slideshow

The following slide deck was published by Genetron Holdings Limited in conjunction with this event....

SA Transcripts on Seeking Alpha | February 17, 2022

Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED''s ORPATHYS® for NSCLC

BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ: GTH ), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM: HCM; HKEX: 13) for the joint development of a companion diagnostic (CDx) test for ORPATHYS ® (savolitinib) in China. Under the agreement, the partners plan to jointly validate and register Genetron Health''s approved NGS-based 8-gene Lung Cancer Assay (Tissue) as CDx for ORPATHYS ® . Developed based on Genetron Health''s proprietary One-step Seq method, the 8-gene Lung Ca...

Benzinga | February 10, 2022

Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMEDs ORPATHYS® for NSCLC

BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM: HCM; HKEX: 13) for the joint development of a companion diagnostic (CDx) test for ORPATHYS ® (savolitinib) in China.

GlobeNewswire | February 10, 2022

Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLC

BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) for the joint development of a companion diagnostic (CDx) test for

Yahoo | February 10, 2022

Inspira, Genetron lead healthcare gainers; Amphastar, NRx Pharmaceuticals among losers

Gainers: Inspira Technologies Oxy (IINN) +23%. Genetron (GTH) +15%

Seeking Alpha | January 31, 2022

Read More 'GTH' Stories Here

GTH Price Returns

1-mo N/A
3-mo -28.31%
6-mo -74.26%
1-year -92.78%
3-year N/A
5-year N/A
YTD -74.26%
2021 -56.43%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4151 seconds.